Ursa Brown Glaberman, MD
Hematology & Oncology · Albuquerque, NMNPI 1821292160
Payments from drug & device makers
Across 428 payments — averaging $11,598 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3.4M
- Seagen Inc.$388K
- Pfizer$285K
- Radius Health, Inc.$185K
- E.r. Squibb & Sons, L.L.C.$148K
- Genentech, Inc.$125K
- plus $430K from 21 others
Across 1 payment — averaging $101,166 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$101K
What the payments were for
- Consulting fees$68,84031%
- Speaking & faculty fees$123,69956%
- Travel & lodging$21,08010%
- Food & beverage$5,2972%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 65 | $3,402,776 |
| Seagen Inc. | 81 | $387,786 |
| Pfizer | 55 | $285,254 |
| Radius Health, Inc. | 8 | $185,454 |
| E.r. Squibb & Sons, L.L.C. | 6 | $147,618 |
| Genentech, Inc. | 16 | $124,516 |
| Taiho Oncology, Inc. | 19 | $115,206 |
| Merck | 21 | $65,031 |
| Gilead | 69 | $63,597 |
| AbbVie | 5 | $48,451 |
| Stemline Therapeutics Inc. | 17 | $41,883 |
| Roche Products Limited | 16 | $29,834 |
| Exelixis Inc. | 4 | $19,938 |
| Macrogenics, Inc. | 5 | $18,415 |
| AstraZeneca | 15 | $10,289 |
| Eli Lilly | 4 | $8,200 |
| Daiichi Sankyo Inc. | 8 | $3,370 |
| Sanofi | 1 | $2,835 |
| Eisai Inc. | 5 | $2,152 |
| Halozyme Inc | 1 | $900 |
| Novocure Inc. | 1 | $131 |
| Sandoz | 1 | $89 |
| Caris MPI, Inc. | 1 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Incyte Corporation | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,963,875 in reported general payments places this provider in the 95th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 24 | $442 |
| Prochlorperazine Maleate | 23 | $356 |
| Ondansetron Hcl | 20 | $178 |
| Gabapentin | 15 | $114 |
| Tramadol Hcl | 13 | $91 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Albuquerque
- Neda Hashemi SadraeiAlbuquerque$1.6M
- Olivier RixeAlbuquerque$1.6M
- Emrullah YilmazAlbuquerque$1.3M
- Erika MaestasAlbuquerque$880K
- Jose AvitiaAlbuquerque$553K
- Jacklyn NemunaitisAlbuquerque$351K
- Barbara McAnenyAlbuquerque$326K
- Zoneddy DayaoAlbuquerque$319K
- Yara AbdouAlbuquerque$294K
- Scott HerbertAlbuquerque$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.